Evidence map›Paper›PMID 40882634›Full record

ArticleCancer cell2025

Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer.

Jennifer R Grandis, Katherine A Skorupski, Ning Cheng, Zhibin Cui, Hua Li, Liam C Woerner, Jovanka Gencel-Augusto, Yan Zeng, Jamie V Shiah, Neil E Bhola and 10 more

Abstract readClinical Trial, Veterinary
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. STAT3 signaling inhibitors for cancer treatment.Trends in pharmacological sciences · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jennifer R GrandisDepartment of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, San Francisco, CA, USA. Electronic address: jennifer.grandis@ucsf.edu.
Katherine A SkorupskiDepartment of Surgical & Radiological Sciences, University of California Davis School of Veterinary Medicine, Davis, CA, USA.
Ning ChengDepartment of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, San Francisco, CA, USA.
Zhibin CuiDepartment of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, San Francisco, CA, USA.
Hua LiDepartment of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, San Francisco, CA, USA.
Liam C WoernerDepartment of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, San Francisco, CA, USA.
Jovanka Gencel-AugustoDepartment of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, San Francisco, CA, USA.
Yan ZengDepartment of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, San Francisco, CA, USA.
Jamie V ShiahDepartment of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, San Francisco, CA, USA.
Neil E BholaDepartment of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, San Francisco, CA, USA.
Malabika SenThe Institute for Precision Medicine, University of Pittsburgh and the University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Kelly BlumHelen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Mi-Ok KimDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
Daniel YorkDepartment of Surgical & Radiological Sciences, University of California Davis School of Veterinary Medicine, Davis, CA, USA.
Robert B RebhunDepartment of Surgical & Radiological Sciences, University of California Davis School of Veterinary Medicine, Davis, CA, USA.
Hong ChangDepartment of Surgical & Radiological Sciences, University of California Davis School of Veterinary Medicine, Davis, CA, USA.
Natalia F MuradDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Adam B OlshenDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
Ellen E SpargerDepartment of Veterinary Medicine and Epidemiology, University of California Davis School of Veterinary Medicine, Davis, CA, USA.
Daniel E JohnsonDepartment of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, San Francisco, CA, USA. Electronic address: daniel.johnson@ucsf.edu.

Funding

Integrating genomics and the protein interactome for HPV+ head and neck cancer therapyR35CA231998 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2018 to 2024
$6.2M
Targeting STAT3 to enhance anti-tumor immunityR01DE028289 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN, JOHNSON, DANIEL E · 2019 to 2023
$3.2M
Particulate Delivery of STING Agonist as Anti-cancer Immuotherapeutics and Cancer MicrobiomeK00CA223019 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHENG, NING · 2019 to 2022
$376k
NCI NIH HHS K00 CA223019NCI NIH HHS R35 CA231998NIDCR NIH HHS R01 DE028289
6 · The paper itself

Abstract

STAT3 is an oncogenic transcription factor that activates cancer cell signaling and induces an immunosuppressive immune environment, making it an attractive therapeutic target. Transcription factors are exceptionally challenging targets and there are no Food and Drug Administration-approved STAT3 inhibitors. We previously reported positive pharmacodynamics of a linear STAT3 decoy oligonucleotide administered intratumorally in a phase 0 trial in patients with head and neck cancer squamous cell carcinoma (HNSCC). Here, we describe the anti-tumor and immune effects of a systemically administered cyclic STAT3 decoy (CS3D) in immunocompetent HNSCC murine models and the safety and efficacy of CS3D in a clinical trial in pet cats with HNSCC. Responders in the clinical trial (35% disease control rate) showed significant differences in selected peripheral blood immune parameters as well as elevated PD-1 expression in the tumors compared with non-responders. These findings support a clinical trial of CS3D in HNSCC patients.

Indexed as

Mouth NeoplasmsOligonucleotidesSquamous Cell Carcinoma of Head and NeckSTAT3 Transcription FactorAnimalsCatsDisease Models, AnimalFemaleMaleMiceOligonucleotidesSTAT3 Transcription Factorclinical trialcyclic STAT3 decoyfeline oral cancerhead and neck canceroral cancerSTAT3STAT3 inhibitor

Identifiers

PMID40882634
PMCPMC12404672

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.